Bibliografia del Gruppo MITO

• Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial.Gynecologic Oncology
  Anne Floquet, Ignace Vergote, Nicoletta Colombo, Bent Fiane, Bradley J. Monk, Alexander Reinthaller, Paula Calvert, Thomas J. Herzog, Werner Meier, Jae-Weon Kim, Josep M. del Campo,Michael Friedlander, Carmela Pisano, Seiji Isonishi, Rocco J. Crescenzo, Catherine Barrett, Karrie Wang, Ionel Mitrica, Andreas du Bois
  Volume 136, Issue 1, January 2015, Pages 37–42
  
  
• Management of Bilateral Malignant Ovarian Germ Cell Tumors: A MITO-9 Retrospective Study.
  Sigismondi C, Scollo P, Ferrandina G, Candiani M, Angioli R, Viganò R, Scarfone G, Mangili G.
  Int J Gynecol Cancer. 2015 Jan 7. [Epub ahead of print]
  
  
• Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial.
  Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M.Gynecol Oncol. 2014 Oct 2. pii: S0090-8258(14)01344-4. doi: 10.1016/j.ygyno.2014.09.017. [Epub ahead of print]
  
  
• Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
  Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12.
  
  
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix.
  Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297.
  
  
• Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors.
  Brown J, Friedlander M, Backes FJ, Harter P, O’Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223.
  
  
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary.
  Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265.
  
  
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary.
  Glasspool RM, Martín AG, Millan D, Lorusso D, Avall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9. doi: 10.1097/IGC.0000000000000209.
  
  
• Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults.
  Mangili G, Sigismondi C, Lorusso D, Pignata S. J Clin Oncol. 2014 Sep 1;32(25):2814-5. doi: 10.1200/JCO.2014.55.9617. Epub 2014 Jul 28. No abstract available.
  
  
• Progression-Free Survival by Local Investigator Versus Independent Central Review: Comparative Analysis of the AGO-OVAR16 Trial.
  Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, Del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Gynecol Oncol. 2014 Nov 27. pii: S0090-8258(14)01547-9
  
  
• Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
  Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. J Clin Oncol. 2014 May 1;32(13):1302-8.
  
  
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus.
  Pautier P, Ji Nam E, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7.
   
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma.
  Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9. 
   
• Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.
  Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ.Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16. 
   
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma.
  Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101. 
   
• Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas.
  Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-S13. 
   
• Incorporation of pazopanib in maintenance therapy of ovarian cancer.
  du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. J Clin Oncol. 2014 Oct 20;32(30):3374-82. 
   
• Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). 
  Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S; OCTAVIA Investigators.Eur J Cancer. 2014 Mar;50(4):862-3. doi: 10.1016/j.ejca.2013.12.001. Epub 2014 Jan 10. No abstract available. 
   
• Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
  Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.Eur J Cancer. 2013 Dec;49(18):3831-8. 
   
• Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
  Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A; member trial groups of the European Network of Gynaecological Trial groups (ENGOT).Int J Gynecol Cancer. 2013 Sep;23(7):1339-43. 
   
• The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
  You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A. Gynecol Oncol. 2013 Aug;130(2):289-94. 
   
• Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
  Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Oncology. 2014;86 (5-6):351-8.
   
• Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
  Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Lancet Oncol. 2014 Apr;15 (4):396-405.
   
• Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. 
  Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting. Int J Gynecol Cancer. 2013 Oct;23(8):1528-34.
   
• Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study.
  Mangili G, Sigismondi C, Frigerio L, Candiani M, Savarese A, Giorda G, Lauria R, Tamberi S, Greggi S, Lorusso D. Gynecol Oncol. 2013 Jul;130(1):38- 42.
   
• Health-related quality of life in recurrent platinum-sensitive ovarian cancer–results from the CALYPSO trial.
  Ann Oncol. 2012 Aug;23(8):2020-7.
   
• Health-related quality of life in recurrent platinum-sensitive ovarian cancer–results from the CALYPSO trial.
  E.Ann Oncol. 2012 Aug;23(8):2020-7.
   
• A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
  Ann Oncol. 2012 Oct 26.
   
• Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
  Ann Oncol. 2012 May;23(5):1185-9.
   
• Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
  Br J Cancer. 2012 Aug 7;107(4):588-91.
   
• Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. Gynecol Oncol.
  2012 Jun;125(3):673-6.
   
• Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors: A MITO-9 Retrospective Study.
  Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, Ferrandina G, Greggi S, Candiani M, Lorusso D. Int J Gynecol Cancer. 2011 Nov;21(8):1414-1421.
   
• Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
  Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. J Clin Oncol. 2011 Sep 20;29(27):3628-35.
   
• Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
  Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.
   
• Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
  Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S. Int J Gynecol Cancer. 2011 Aug;21(6):1063-70.
   
• Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
  Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12.
   
• Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
  Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Gynecol Oncol. 2011 May 1;121(2):280-4.
   
• Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
  Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M,Reinthaller A, Vergote I, Ferrandina G, Dell’anna T, Huober J, Pujade-Lauraine E.Gynecol Oncol. 2011 May 14.
   
• Clinical trials in recurrent ovarian cancer.
  Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):771-5.
   
• Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
  Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):763-70.
   
• Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
  Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; onbehalf of Gynecologic Cancer Intergroup. Ann Oncol. 2011 Mar 14.
   
• Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
  Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Int J Gynecol Cancer. 2011 Feb;21(2):289-95.
   
• Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
  Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Gynecol Oncol. 2011 Jan 27.
   
• European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and pharmaceutical companies.
  Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups. Int J Gynecol Cancer. 2010; 20(3):476-8
   
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
  Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. J Clin Oncol. 2010 10;28(20):3323-9
   
• Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
  Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Ann Oncol. 2010; 21(1):61-6.
   
• Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup.
  Small W Jr, Du Bois A, Bhatnagar S, Reed N, Pignata S, Potter R, Randall M, Mirza M, Trimble E, Gaffney D; Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2009; 19(3):395-9.
   
• A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
  Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. Cancer Chemother Pharmacol. 2009 Mar 6.
   
• Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study.
  Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble EL. Int J Gynecol Cancer. 2009 Jan;19(1):163-7.
   
• Endometrial cancer state of the science meeting.
  Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Int J Gynecol Cancer. 2009 Jan;19(1):134-40.
   
• Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R,Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A. Crit Rev Oncol Hematol. 2009 Jan 27. Epub ahead of print
   
• Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial.
  Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Oncology. 2009 76: 49-54
   
• Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
  Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G. Br J Cancer. 2008; 98:1910-5.
   
• Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. BMC Cancer. 2008; 8:252
   
• Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
  Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. J Clin Oncol. 2008; 20;26(6):890-6.
   
• A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
  Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.Crit Rev Oncol Hematol. 2008; 66(3):229-36.
   
• Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Oncology. 2007;71(5-6):320-6.
   
• A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
  Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. Br J Cancer. 2007;4; 96(11):1639-43.
   
• Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).
  Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Pötter R, Colombo A, Randall M, Mirza MR, Trimble EL. Int J Radiat Oncol Biol Phys. 2007; 68(2):485-90.
   
• Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
  Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D’Arco AM, Sorio R,Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators.BMC Cancer. 2006; 6:202.
   
• Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
  Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F. BMC Cancer. 2006 7;6:5.
   
• Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
  De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. J Clin Oncol. 2004 Jul 1;22(13):2635-42.
   
• Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
  Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau’ F, Scambia G; Multicenter Italian Trials in Ovarian Cancer invesitgators.Ann Oncol. 2003;14(7):1086-93.
   
• Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors: A MITO-9 Retrospective Study.
  Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, Ferrandina G, Greggi S, Candiani M, Lorusso D. Int J Gynecol Cancer. 2011 Nov;21(8):1414-1421.
   
• Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
  Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. J Clin Oncol. 2011 Sep 20;29(27):3628-35.
   
• Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
  Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.
   
• Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
  Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S. Int J Gynecol Cancer. 2011 Aug;21(6):1063-70.
   
• Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
  Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Gynecol Oncol. 2011 May 1;121(2):280-4.
   
• Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
  Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M,Reinthaller A, Vergote I, Ferrandina G, Dell’anna T, Huober J, Pujade-Lauraine E.Gynecol Oncol. 2011 May 14.
   
• Clinical trials in recurrent ovarian cancer.
  Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):771-5.
   
• Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
  Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; onbehalf of Gynecologic Cancer Intergroup. Ann Oncol. 2011 Mar 14.
   
• Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
  Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Gynecol Oncol. 2011 Jan 27.
   
• European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and pharmaceutical companies.
  Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups. Int J Gynecol Cancer. 2010; 20(3):476-8
   
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
  Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. J Clin Oncol. 2010 10;28(20):3323-9
   
• Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
  Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Ann Oncol. 2010; 21(1):61-6.
   
• Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup.
  Small W Jr, Du Bois A, Bhatnagar S, Reed N, Pignata S, Potter R, Randall M, Mirza M, Trimble E, Gaffney D; Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2009; 19(3):395-9.
   
• A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
  Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. Cancer Chemother Pharmacol. 2009 Mar 6.
   
• Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study.
  Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble EL. Int J Gynecol Cancer. 2009 Jan;19(1):163-7.
   
• Endometrial cancer state of the science meeting.
  Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Int J Gynecol Cancer. 2009 Jan;19(1):134-40.
   
• Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R,Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A. Crit Rev Oncol Hematol. 2009 Jan 27. Epub ahead of print
   
• Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial.
  Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Oncology. 2009 76: 49-54
   
• Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
  Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G. Br J Cancer. 2008; 98:1910-5.
   
• Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. BMC Cancer. 2008; 8:252
   
• Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
  Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. J Clin Oncol. 2008; 20;26(6):890-6.
   
• A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
  Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.Crit Rev Oncol Hematol. 2008; 66(3):229-36.
   
• Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
  Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Oncology. 2007;71(5-6):320-6.
   
• A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
  Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. Br J Cancer. 2007;4; 96(11):1639-43.
   
• Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).
  Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Pötter R, Colombo A, Randall M, Mirza MR, Trimble EL. Int J Radiat Oncol Biol Phys. 2007; 68(2):485-90.
   
• Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
  Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D’Arco AM, Sorio R,Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators.BMC Cancer. 2006; 6:202.
   
• Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
  Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F. BMC Cancer. 2006 7;6:5.
   
• Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
  De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. J Clin Oncol. 2004 Jul 1;22(13):2635-42.
   
• Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
  Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau’ F, Scambia G; Multicenter Italian Trials in Ovarian Cancer invesitgators.Ann Oncol. 2003;14(7):1086-93.
  
• Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282.
  Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A. Review. PubMed PMID: 25341581.
  
• Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi:10.1097/IGC.0000000000000249.
  Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N. Review. PubMed PMID: 25341579
  
• Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014 Nov;24 (9 Suppl 3):S20-5. doi:10.1097/IGC.0000000000000289. 
  Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A. Review. Erratum in: Int J Gynecol Cancer. 2015 May;25(4):721. Mezzazanica, Delia [corrected to Mezzanzanica, Delia]. PubMed
  PMID: 25341576.
  
  
• Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions Cells. 2019 Feb 26;8(3). pii: E200. doi: 10.3390/cells8030200
  
  Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D
  PMID: 30813545